Syncona

Spur provides update on FLT201 and planned phase III clinical trial

8 July 2024 -- London, UK -- Syncona Ltd, a leading life science investor focused on creating, building and scaling global leaders in life science, notes that its portfolio company Spur Therapeutics has completed enrolment in the phase 1/2 GALILEO-1 clinical trial of FLT201, its adeno-associated virus (AAV) gene therapy candidate for Gaucher disease. Based...
2nd Floor, 8 Bloomsbury Street, London, WC1B 3SR

020 3981 7909